» Articles » PMID: 24802708

MiR-129-3p, As a Diagnostic and Prognostic Biomarker for Renal Cell Carcinoma, Attenuates Cell Migration and Invasion Via Downregulating Multiple Metastasis-related Genes

Overview
Specialty Oncology
Date 2014 May 8
PMID 24802708
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Downregulation of miRNA expression has been identified as a novel feature of renal cell carcinoma (RCC). Recently, miR-129-2 is well known to be frequently reduced by DNA methylation and has anti-tumor effects in various tumors but so far not in RCC. The aim of this study was to investigate the clinical significance and the role of it in RCC.

Methods: The expression levels of miR-129-3p and miR-129-5p, two mature products of miR-129-2, were determined by real-time quantitative reverse transcription PCR in 69 cases of paired different kidney tumors and normal tissues and clear cell RCC (ccRCC) cell lines. The roles of them in RCC cells were assessed by functional analyses. Protein expression was detected by Western blot.

Results: miR-129-3p, but not miR-129-5p, was widely attenuated in human ccRCC, and chromophobe RCC. miR-129-3p could yield 73.5 % accuracy in discriminating ccRCCs from normal tissues. The relative miR-129-3p expression significantly differed between malignant and benign kidney tumors. Importantly, low miR-129-3p levels were associated with short disease-free and overall survival. Ectopic expression of miR-129-3p robustly impaired RCC cell migratory and invasive properties, but had no impact on cell viability and cell cycle distribution. Finally, miR-129-3p decreased multiple metastasis-related genes in RCC cells, including SOX4, phosphorylation of focal adhesion kinase and MMP-2/9 expression.

Conclusions: miR-129-3p may act as a promising diagnostic biomarker for discriminating ccRCC from benign tumors and normal tissues and an independent prognostic biomarker in ccRCC. miR-129-3p may exert its anti-metastatic function through modulating multiple targets.

Citing Articles

MicroRNA-129-3p Suppresses Tumor Progression and Chemoradioresistance in Head and Neck Squamous Cell Carcinoma.

Yoon T, Kim S, Jung E, Kim Y, Lee K, Lim S Curr Oncol. 2025; 32(1).

PMID: 39851970 PMC: 11763343. DOI: 10.3390/curroncol32010054.


Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.

Sirek T, Krol-Jatrega K, Borawski P, Zmarzly N, Boron D, Ossowski P Front Oncol. 2025; 14():1515387.

PMID: 39850811 PMC: 11754234. DOI: 10.3389/fonc.2024.1515387.


The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges.

Garcia C, Grisetti L, Tiribelli C, Pascut D Life (Basel). 2024; 14(11).

PMID: 39598228 PMC: 11595987. DOI: 10.3390/life14111430.


Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study.

Deng J, Tu S, Li L, Li G, Zhang Y Cancer Rep (Hoboken). 2024; 7(6):e2116.

PMID: 38837683 PMC: 11150078. DOI: 10.1002/cnr2.2116.


A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment.

Zhang Q, Ren H, Ge L, Zhang W, Song F, Huang P Cancer Cell Int. 2023; 23(1):16.

PMID: 36732762 PMC: 9893571. DOI: 10.1186/s12935-023-02861-6.


References
1.
Chen X, Zhang L, Zhang T, Hao M, Zhang X, Zhang J . Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int. 2013; 33(3):476-86. DOI: 10.1111/liv.12097. View

2.
Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R . Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013; 108(1):131-8. PMC: 3553529. DOI: 10.1038/bjc.2012.537. View

3.
Kang M, Li Y, Liu W, Wang R, Tang A, Hao H . miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. Int J Mol Med. 2013; 32(1):51-8. DOI: 10.3892/ijmm.2013.1384. View

4.
Seike M, Goto A, Okano T, Bowman E, Schetter A, Horikawa I . MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A. 2009; 106(29):12085-90. PMC: 2715493. DOI: 10.1073/pnas.0905234106. View

5.
Hildebrandt M, Gu J, Lin J, Ye Y, Tan W, Tamboli P . Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010; 29(42):5724-8. DOI: 10.1038/onc.2010.305. View